| Autor: |
Hao Li, Xia-Ming Jiang, Ning Cui, Chun Yuan, Shao-Fei Zhang, Qing-Bin Lu, Zhen-Dong Yang, Qin-Lin Xin, Ya-Bin Song, Xiao-Ai Zhang, Hai-Zhou Liu, Juan Du, Xue-Juan Fan, Lan Yuan, Yi-Mei Yuan, Zhen Wang, Juan Wang, Lan Zhang, Dong-Na Zhang, Zhi-Bo Wang, Ke Dai, Jie-Ying Bai, Zhao-Nian Hao, Hang Fan, Li-Qun Fang, Gengfu Xiao, Yang Yang, Ke Peng, Hong-Quan Wang, Jian-Xiong Li, Lei-Ke Zhang, Wei Liu |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Signal Transduction and Targeted Therapy, Vol 6, Iss 1, Pp 1-13 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2059-3635 |
| DOI: |
10.1038/s41392-021-00541-3 |
| Popis: |
Abstract Severe fever with thrombocytopenia syndrome (SFTS) virus (SFTSV) is an emerging tick-borne virus with high fatality and an expanding endemic. Currently, effective anti-SFTSV intervention remains unavailable. Favipiravir (T-705) was recently reported to show in vitro and in animal model antiviral efficacy against SFTSV. Here, we conducted a single-blind, randomized controlled trial to assess the efficacy and safety of T-705 in treating SFTS (Chinese Clinical Trial Registry website, number ChiCTR1900023350). From May to August 2018, laboratory-confirmed SFTS patients were recruited from a designated hospital and randomly assigned to receive oral T-705 in combination with supportive care or supportive care only. Fatal outcome occurred in 9.5% (7/74) of T-705 treated patients and 18.3% (13/71) of controls (odds ratio, 0.466, 95% CI, 0.174–1.247). Cox regression showed a significant reduction in case fatality rate (CFR) with an adjusted hazard ratio of 0.366 (95% CI, 0.142–0.944). Among the low-viral load subgroup (RT-PCR cycle threshold ≥26), T-705 treatment significantly reduced CFR from 11.5 to 1.6% (P = 0.029), while no between-arm difference was observed in the high-viral load subgroup (RT-PCR cycle threshold |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
